MCID: DDF001
MIFTS: 41

Dedifferentiated Liposarcoma malady

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Dedifferentiated Liposarcoma

About this section
Sources:
51Orphanet, 65UMLS, 28ICD10 via Orphanet, 66UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Dedifferentiated Liposarcoma:

Name: Dedifferentiated Liposarcoma 51
Liposarcoma, Dedifferentiated 65
 
Ddls 51

Characteristics:

Orphanet epidemiological data:

51
dedifferentiated liposarcoma:
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Adult; Age of death: adult

Classifications:

Orphanet: 51 
Rare tumors


External Ids:

Orphanet51 99970
ICD10 via Orphanet28 C49.9
UMLS via Orphanet66 C0205824
UMLS65 C0205824

Summaries for Dedifferentiated Liposarcoma

About this section
MalaCards based summary: Dedifferentiated Liposarcoma, also known as liposarcoma, dedifferentiated, is related to glioma and hepatocellular carcinoma. An important gene associated with Dedifferentiated Liposarcoma is MDM2 (MDM2 Proto-Oncogene), and among its related pathways are Oncogene Induced Senescence and RB in Cancer. Affiliated tissues include testes, t cells and breast, and related mouse phenotypes are pigmentation and no phenotypic analysis.

Related Diseases for Dedifferentiated Liposarcoma

About this section

Diseases related to Dedifferentiated Liposarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 234)
idRelated DiseaseScoreTop Affiliating Genes
1glioma29.6CDK4, CDKN2A, MDM2, MET, PTEN, RB1
2hepatocellular carcinoma28.6CDK4, CDKN2A, KIT, MDM2, MET, PSMD10
3primary malignant melanoma of the cervix10.5CDKN2A, PTEN
4anaplastic ganglioglioma10.5MDM2, PTEN
5fibrosarcoma of bone10.5CDK4, MDM2
6small cell osteogenic sarcoma10.5CDK4, MDM2
7epithelioid sarcoma10.5CDK4, MDM2
8deep leiomyoma10.5ACTC1, CDKN2A
9autosomal dominant medullary cystic kidney disease with hyperuricemia10.5CDKN2A, PTEN
10angiolipoma10.5CDK4, CDKN2A, MDM2
11amelogenesis imperfecta hypomaturation type10.4CDKN2A, SDC1
12bowing of legs, anterior with dwarfism10.4CDKN2A, PPARG
13dubin-johnson syndrome10.4CDK4, CDKN2A, PTEN
14benign mesenchymoma10.4ACTC1, CDKN2A, PTEN
15arthritis10.4
16leukemia10.4
17endotheliitis10.4
18middle ear squamous cell carcinoma10.4CDKN2A, MDM2
19malignant epithelial mesothelioma10.4ACTC1, CDKN2A
20pleomorphic xanthoastrocytoma10.4CDK4, CDKN2A, PTEN
21adult astrocytic tumour10.3MDM2, PPARG, PTEN
22autosomal dominant charcot-marie-tooth disease type 2f10.3IGF1R, PPARG, PTEN
23osteomyelitis10.3HMGA2, PTEN
24juvenile astrocytoma10.3CDK4, CDKN2A, MDM2, PTEN
25vibratory urticaria10.3CDKN2A, MET, PTEN
26bone peripheral neuroepithelioma10.3HMGA2, MDM2
27hepatitis10.3
28lymphoma10.3
29lupus erythematosus10.3MET, PPARG, PTEN
30acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor10.3CEBPA, KIT
31pacinian tumor10.3HMGA2, MDM2
32acute myeloid leukemia, kit-related10.3CEBPA, KIT
33gliosarcoma10.3CDK4, CDKN2A, MDM2, PTEN
34acute myeloblastic leukemia without maturation10.3CEBPA, KIT
35tendon sheath lipoma10.3CDK4, HMGA2, MDM2
36sebaceous breast carcinoma10.3CDK4, KIT, MDM2
37mucosal melanoma10.2KIT, PTEN
38vitamin d-dependent rickets, type i10.2CDK4, HMGA2, MDM2
39nezelof syndrome10.2CDK4, KIT, MDM2
40breast cancer10.2
41polycystic ovary syndrome10.2
42heart disease10.2
43hyperparathyroidism10.2
44severe acute respiratory syndrome10.2
45pancreatitis10.2
46pneumonia10.2
47t-cell leukemia10.2
48thyroiditis10.2
49neuronitis10.2
50muscular dystrophy10.2

Graphical network of the top 20 diseases related to Dedifferentiated Liposarcoma:



Diseases related to dedifferentiated liposarcoma

Symptoms for Dedifferentiated Liposarcoma

About this section

Drugs & Therapeutics for Dedifferentiated Liposarcoma

About this section

Drugs for Dedifferentiated Liposarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 13)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Trabectedinapproved, investigationalPhase 258114899-77-3108150
Synonyms:
ET-743
ET743
Ecteinascidin
 
Ecteinascidin 743
NSC 684766
SID144206315
SID144206787
Yondelis
2
Rosiglitazoneapproved, investigationalPhase 2220122320-73-477999
Synonyms:
(RS)-5-{4-[2-(Methyl-2-pyridylamino)ethoxy]benzyl}-2,4-thiazolidinedion
(±)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione
122320-73-4
2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI)
5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
5-((4-(2-Methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate
5-(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione
5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
5-[[4-[2-(methyl-(2-pyridyl)amino)ethoxy]phenyl]methyl] thiazolidine-2,4-dione
5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
AC-3459
AC1L2U9N
Avandia
BRD-A97437073-001-02-3
BRD-A97437073-001-03-1
BRL49653
BSPBio_002693
Brl 49653
Brl-49653
C18H19N3O3S
CID77999
D08491
DB00412
Gaudil
Gaudil (TN)
HMS1922J11
HMS2094O13
HSDB 7555
I06-0141
IDMB (1uM BRL49653, 1uM Dexamethasone, 0.5uM IBMX, 10ug/mL Insulin)
KBio2_002183
KBio2_004751
KBio2_007319
KBio3_001913
KBioGR_001609
 
KBioSS_002183
LS-151340
MolPort-002-508-212
NCGC00095124-01
NCGC00095124-02
NCGC00095124-03
RGZ
RSG
Rosi
Rosigilitazone
Rosigliazone maleate
Rosiglitazon
Rosiglitazona
Rosiglitazone
Rosiglitazone (INN)
Rosiglitazone Maleate
Rosiglitazone [INN:BAN]
Rosiglitazone maleate
Rosiglitazonum
Rosiglizole
S00306
SPBio_001142
SPECTRUM1504263
STOCK6S-23924
Spectrum2_001241
Spectrum3_000997
Spectrum4_001125
Spectrum5_001464
Spectrum_001703
TDZ 01
UNII-05V02F2KDG
[3H]rosiglitazone
rosiglitazona
rosiglitazone
rosiglitazone (Avandia)
rosiglitazonum
3PembrolizumabapprovedPhase 22881374853-91-4
4
IfosfamideapprovedPhase 23713778-73-23690
Synonyms:
(+-)-Ifosfamid
(+-)-Ifosphamide
(+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
(D,L)-Ifosfamide
(R,S)-Ifosphamide
(R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd
2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis( 2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI)
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
3,} 2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2- oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
36341-88-5
3778-73-2
84711-20-6
A 4942
AB00513932
AC-2113
AC1L1GHW
ASTA Z 4942
Ambap3778-73-2
Asta Z 4942
BPBio1_000865
BRN 0611835
BSPBio_000785
C07047
CAS-3778-73-2
CCRIS 352
CHEBI:5864
CHEMBL1024
CID3690
Cyfos
D00343
D007069
DB01181
EINECS 223-237-3
HMS1570H07
HMS2090M12
HMS2093N07
HSDB 7023
Holoxan
Holoxan 1000
I-Phosphamide
I06-0494
IFEX (TN)
Ifex
Ifosfamid
Ifosfamida
Ifosfamida [INN-Spanish]
Ifosfamide
 
Ifosfamide (JAN/USP/INN)
Ifosfamide Sterile
Ifosfamide [USAN:INN:BAN:JAN]
Ifosfamidum
Ifosfamidum [INN-Latin]
Ifosphamide
Ifsofamide
Iphosphamid
Iphosphamid(e)
Iphosphamide
Iso Endoxan
Iso-Endoxan
Isoendoxan
Isofosfamide
Isophosphamide
Isosfamide
LS-102
LS-99799
MJF 9325
MJF-9325
MLS002154021
Mitoxana
Mitoxana, Ifex, Ifosfamide
MolPort-003-666-704
N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide
N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine
NCGC00016639-01
NCGC00179435-01
NCI-C01638
NCI60_000233
NPFAPI-04
NSC 109,724
NSC 109724
NSC-109,724
NSC-109724
NSC109,724
NSC109724
Naxamide
Prestwick0_000833
Prestwick1_000833
Prestwick2_000833
Prestwick3_000833
S1302_Selleck
SMR001233348
SPBio_002706
STL058690
UNII-UM20QQM95Y
WLN: T6NPOTJ AM2G BO B2G
Z 4942
Z-4942
Z4942
ifosfamide
isosfamide
{3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,
5
MechlorethamineapprovedPhase 230951-75-24033
Synonyms:
.Beta.,.beta.'-Dichlorodiethyl-N-methylamine
1, 5-Dichloro-3-methyl-3-azapentane hydrochloride
126-85-2 (N-oxide)
2,2'-Dichloro-N-me
2,2'-Dichloro-N-methyldiethylamine
2,2'-Dichlorodiethyl-methylamine
2,2'-dichloro-N-methyldiethylamine
2-Chloro-N-(2-chloroethyl)-N-methylethanamine
302-70-5 (N-oxide, hydrochloride)
51-75-2
55-86-7 (HYDROCHLORIDE)
AC1L1H9H
Antimit
BRN 0605323
BSPBio_001947
Bis(2-chloroethyl)methylamine
Bis(beta-chloroethyl) methylamine
Bis(beta-chloroethyl)methylamine
C07115
C5H11Cl2N
CCRIS 447
CHEBI:28925
CHEMBL427
CID4033
Carolysine
Caryolysin
Caryolysine
Chloramine (the nitrogen mustard)
Chlorethazine
Chlormethine
Chlormethine (INN)
Chlormethine [INN:BAN]
Chlormethinum [INN-Latin]
Cloramin
Clormetina
Clormetina [INN-Spanish]
D07671
DB00888
Di(2-chloroethyl)methylamine
Dichlor amine
Dichloren
DivK1c_000759
EINECS 200-120-5
ENT-25294
Embechine
Embichin
HMS1920J15
HMS2091B04
HMS502F21
HN-2
HN2
HSDB 5083
I14-8708
IBS-L0033631
IDI1_000759
KBio1_000759
KBio2_001369
KBio2_003937
KBio2_006505
KBio3_001447
KBioGR_001448
 
KBioSS_001369
LS-7559
MBA
Me chloroethamine
Mebichloramine
Mechlorethamine
Mechlorethamine hydrochloride
Mechlorethanamine
Mechloroethamine
Mecloretamina
Mecloretamina [Italian]
Methylbis(2-chloroethyl)amine
Methylbis(beta-chloroethyl)amine
Methyldi(2-chloroethyl)amine
Mitoxine (*Hydrochloride*)
MolPort-001-785-592
Mustargen
Mustine
Mustine note
Mutagen
N,N-Bis(2-chloroethyl)-N-methylamine
N,N-Bis(2-chloroethyl)methylamine
N,N-Di(chloroethyl)methylamine
N-Lost
N-Methyl lost
N-Methyl-2,2'-dichlorodiethylamine
N-Methyl-bis(2-chloroethyl)amine
N-Methyl-bis(beta-chloroethyl)amine
N-Methyl-bis-chloraethylamin
N-Methyl-bis-chloraethylamin [German]
N-Methyl-lost
N-Methyl-lost [German]
N-methyl-bis(2-chloroethyl)amine
NCGC00091835-02
NCGC00091835-03
NCGC00091835-04
NCGC00091835-05
NCI60_041682
NINDS_000759
NSC762
Nitol (*Hydrochloride*)
Nitrogen mustard
Nitrogen mustard (HN-2)
Nitrogranulogen
SPBio_000496
SPECTRUM1500375
Spectrum2_000448
Spectrum3_000484
Spectrum4_000924
Spectrum5_001702
Spectrum_000889
Stickstofflost (*Hydrochloride*)
Stickstofflost (ebewe)
T 1024
T-1024
TL 146
UNII-50D9XSG0VR
Valchlor
beta,Beta'-dichlorodiethyl-N-methylamine
beta,beta'-Dichlorodiethyl-N-methylamine
mechlorethamine
thyldiethylamine
β,β'-dichlorodiethyl-N-methylamine
6
Maleic acidexperimentalPhase 2274110-16-7444972, 444266
Synonyms:
(2Z)-2-Butenedioate
(2Z)-2-Butenedioic acid
(2Z)-Butene-2-dioate
(2Z)-Butene-2-dioic acid
(2Z)-but-2-enedioate
(2Z)-but-2-enedioic acid
(Z)-2-Butenedioate
(Z)-2-Butenedioic acid
(z)-butenedioate
(z)-butenedioic acid
2-Butenedioate
2-Butenedioic acid
Cis-butenedioate
Cis-butenedioic acid
 
H2male
Kyselina maleinova
MAE
Maleate
Maleic acid
Maleic acid [NA2215]
Maleinic acid
Malenic acid
Malezid CM
Scotchbond multipurpose etchant
Toxilic acid
cis-1,2-Ethylenedicarboxylic acid
cis-2-Butenedioate
cis-2-Butenedioic acid
cis-But-2-enedioate
cis-But-2-enedioic acid
7Antineoplastic Agents, AlkylatingPhase 23406
8Alkylating AgentsPhase 23582
9AntibodiesPhase 24477
10Hypoglycemic AgentsPhase 24503
11ImmunoglobulinsPhase 24477
12
MesnaPhase 22433375-50-6598
Synonyms:
2-Mercaptoethanesulfonate
2-Mercaptoethanesulfonic acid
 
CoM
Coenzyme M
HS-CoM
13Isophosphamide mustardPhase 2371

Interventional clinical trials:

idNameStatusNCT IDPhase
1Selinexor in Advanced LiposarcomaRecruitingNCT02606461Phase 2, Phase 3
2Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated LiposarcomaRecruitingNCT02247544Phase 2
3Rosiglitazone in Treating Patients With LiposarcomaActive, not recruitingNCT00004180Phase 2
4Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical TrialActive, not recruitingNCT01692496Phase 2
5SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced SarcomasActive, not recruitingNCT02301039Phase 2
6A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated LiposarcomaNot yet recruitingNCT02571829Phase 2
7Ph II Cabazitaxel/Ifosfamide DD LiposarcomaSuspendedNCT01913652Phase 2
8Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter TrialTerminatedNCT01876043Phase 2
9Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated LiposarcomaWithdrawnNCT00969917Phase 2
10Phase 1 Safety Testing of SAR405838Active, not recruitingNCT01636479Phase 1

Search NIH Clinical Center for Dedifferentiated Liposarcoma

Genetic Tests for Dedifferentiated Liposarcoma

About this section

Anatomical Context for Dedifferentiated Liposarcoma

About this section

MalaCards organs/tissues related to Dedifferentiated Liposarcoma:

33
Testes, T cells, Breast, Lung, Bone, Thyroid, Ovary

Animal Models for Dedifferentiated Liposarcoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Dedifferentiated Liposarcoma:

38 (show all 28)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00011869.1CDK4, CDKN2A, KIT, MDM2, PTEN, RB1
2MP:00030128.5CDKN2A, CEBPA, KIT, MDM2, MET, PPARG
3MP:00053718.3FRS2, IGF1R, KIT, MDM2, MET, PTEN
4MP:00053888.3CDKN2A, CEBPA, IGF1R, KIT, MET, PTEN
5MP:00053818.1CDK4, CDKN2A, CEBPA, IGF1R, KIT, MDM2
6MP:00028738.0ACTC1, CDK4, CEBPA, KIT, MDM2, MET
7MP:00053677.8CDK4, CEBPA, FRS2, KIT, MDM2, MET
8MP:00053907.7CDKN2A, FRS2, IGF1R, KIT, MDM2, PPARG
9MP:00053707.5CDK4, CDKN2A, CEBPA, IGF1R, KIT, MDM2
10MP:00053917.4CDK4, CDKN2A, CEBPA, FRS2, KIT, MET
11MP:00053867.2CDK4, CDKN2A, CEBPA, DES, IGF1R, KIT
12MP:00053807.1CALR, CDK4, CDKN2A, FRS2, IGF1R, KIT
13MP:00036317.0CALR, CDK4, CDKN2A, FRS2, IGF1R, KIT
14MP:00053797.0CDK4, CDKN2A, CEBPA, KIT, MDM2, MET
15MP:00107717.0CDK4, CDKN2A, CEBPA, IGF1R, KIT, MDM2
16MP:00053897.0CDK4, CDKN2A, CEBPA, IGF1R, KIT, MDM2
17MP:00020066.7CDK4, CDKN2A, CEBPA, IGF1R, KIT, MDM2
18MP:00053976.7CDK4, CDKN2A, CEBPA, IGF1R, KIT, MDM2
19MP:00053696.7ACTC1, CALR, CDK4, CDKN2A, CEBPA, DES
20MP:00053876.4CDK4, CDKN2A, CEBPA, IGF1R, KIT, MDM2
21MP:00053856.0ACTC1, CALR, CDK4, CDKN2A, CEBPA, DES
22MP:00053786.0ACTC1, CALR, CDK4, CDKN2A, CEBPA, FRS2
23MP:00053845.6ACTC1, CALR, CDK4, CDKN2A, CEBPA, DES
24MP:00053765.0ACTC1, CALR, CDK4, CDKN2A, CEBPA, DES
25MP:00107684.9ACTC1, CALR, CDK4, CDKN2A, CEBPA, DES

Publications for Dedifferentiated Liposarcoma

About this section

Articles related to Dedifferentiated Liposarcoma:

(show top 50)    (show all 164)
idTitleAuthorsYear
1
A functional insertion/deletion polymorphism in the promoter region of the NFKB1 gene increases the risk of papillary thyroid carcinoma. (25692306)
2015
2
What is the fate of clubfoot patients treated by posteromedial release? (25854655)
2015
3
Pancreatic Duct Drainage for the Treatment of A Huge Pancreatic Cyst Associated with Autoimmune Pancreatitis. (25818079)
2015
4
Coexistence of mature cystic teratoma and adenocarcinoma in situ within atypical proliferative mucinous tumour of ovary--a case report of 35-year-old woman. (26050362)
2015
5
Urethral Diverticulum Masquerading as Anterior Vaginal Wall Cyst: A Diagnostic Dilemma. (26557574)
2015
6
Soluble-E-cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers. (23776059)
2014
7
Accuracy of in vivo confocal microscopy for diagnosis of basal cell carcinoma: a comparative study between handheld and wide-probe confocal imaging. (25338750)
2014
8
Intermittent pneumatic compression is effective in reducing venous thromboembolism risk in hospitalised patients. (24361752)
2013
9
Association of the gonadotrophin-regulated testicular RNA helicase gene polymorphism with human male infertility. (24168058)
2013
10
MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2). (23780685)
2013
11
New advances in the mechanisms and etiology of carpal tunnel syndrome. (22642915)
2012
12
Surgical treatment of gynecomastia: complications and outcomes. (21712702)
2012
13
Adult coats' disease successfully managed with the dexamethasone intravitreal implant (ozurdexAr) combined with retinal photocoagulation. (22548046)
2012
14
Response of pulp sensibility test is strongly influenced by periodontal attachment loss and gingival recession. (22515882)
2012
15
Evaluation of a rapid dipstick test for identifying cholera cases during the outbreak. (22664501)
2012
16
Diagnosis of a biliary cystadenoma demonstrating communication with the biliary system by MRI using a hepatocyte-specific contrast agent. (22308224)
2012
17
Endometrial and ovarian cancer in lynch syndrome. (23730224)
2012
18
A functional polymorphism in the pre-miR-146a gene is associated with risk and prognosis in adult glioma. (21744077)
2011
19
Pelvic MRI in a 17-year-old XY girl with 5-alpha reductase deficiency and a homozygous Gly115Asp mutation in SRD5A2. (21835392)
2011
20
PHF6 mutations in T-cell acute lymphoblastic leukemia. (20228800)
2010
21
Akt phosphorylation of merlin enhances its binding to phosphatidylinositols and inhibits the tumor-suppressive activities of merlin. (19351837)
2009
22
Factor XII C46T gene polymorphism and the risk of cerebral venous thrombosis. (18180442)
2008
23
Responses of Chinese elderly to the threat of severe acute respiratory syndrome (SARS) in a Canadian community. (18173586)
2008
24
Novel toxic shock syndrome toxin-1 amino acids required for biological activity. (19012411)
2008
25
Endobronchial ultrasound appearance of pulmonary artery thrombus in a patient with thymic carcinoma. (17805065)
2007
26
Scrub typhus-associated acute disseminated encephalomyelitis. (17214088)
2006
27
An improved synthesis of psammaplin A. (16632351)
2006
28
The 23 gauge capsulorrhexis forceps having a cystotome function. (15952293)
2005
29
Clinical trials of intracellular signal transductions inhibitors for breast cancer--a strategy to overcome endocrine resistance. (16113091)
2005
30
Expression and regulation of cryopyrin and related proteins in rheumatoid arthritis synovium. (15498798)
2005
31
Hereditary Melkersson-Rosenthal syndrome and multiple sclerosis. (15957522)
2005
32
Simvastatin augments lipopolysaccharide-induced proinflammatory responses in macrophages by differential regulation of the c-Fos and c-Jun transcription factors. (15187114)
2004
33
TRPC channel interactions with calmodulin and IP3 receptors. (15104175)
2004
34
Glycoprotein 130 ligand oncostatin-M induces expression of vascular endothelial growth factor in human adult cardiac myocytes. (14499864)
2003
35
Potentiation of capsaicin receptor activity by metabotropic ATP receptors as a possible mechanism for ATP-evoked pain and hyperalgesia. (11371611)
2001
36
Waardenburg syndrome type 3 (Klein-Waardenburg syndrome) segregating with a heterozygous deletion in the paired box domain of PAX3: a simple variant or a true syndrome? (11683776)
2001
37
Spontaneous regression of bilateral surrenal haematoma and subclinical hypoaldosteronism in a patient with renal amyloidosis secondary to Familial Mediterranean Fever. (11229653)
2000
38
Changes in selected biochemical parameters during a low-calorie reducing diet]. (10953640)
2000
39
Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. (10728757)
2000
40
An analysis of 14 molecular markers for monitoring osteoarthritis: segregation of the markers into clusters and distinguishing osteoarthritis at baseline. (10806045)
2000
41
Analysis of three dental fluorosis indexes used in epidemiologic trials. (10863387)
1999
42
Double-layered patella in multiple epiphyseal dysplasia: a valuable clue in the diagnosis. (9449113)
1998
43
Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC). (9840931)
1998
44
Cleavage of Chordin by Xolloid metalloprotease suggests a role for proteolytic processing in the regulation of Spemann organizer activity. (9363949)
1997
45
Protease-dependent T cell activation: ligation of effector cell protease receptor-1 (EPR-1) stimulates lymphocyte proliferation. (8181072)
1994
46
Differential regulation of carcinoembryonic antigen and biliary glycoprotein by gamma-interferon. (8453631)
1993
47
Divergent effects of interleukin-4 (IL-4) on the granulocyte colony-stimulating factor and IL-3-supported myeloid colony formation from normal and leukemic bone marrow cells. (1688720)
1990
48
Splenic abscess due to Clostridium septicum in a patient with multiple myeloma. (3660050)
1987
49
Endocytosis of the transferrin receptor requires the cytoplasmic domain but not its phosphorylation site. (3568132)
1987
50
Failure of human milk therapy in Menkes' kinky hair disease. (581719)
1979

Variations for Dedifferentiated Liposarcoma

About this section

Expression for genes affiliated with Dedifferentiated Liposarcoma

About this section
Search GEO for disease gene expression data for Dedifferentiated Liposarcoma.

Pathways for genes affiliated with Dedifferentiated Liposarcoma

About this section

Pathways related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

(show all 39)
idSuper pathwaysScoreTop Affiliating Genes
19.8CDK4, CDKN2A, MDM2
29.6CDK4, MDM2, RB1
39.6CDKN2A, MDM2, RB1
49.6CDKN2A, MDM2, RB1
5
Show member pathways
9.6CDKN2A, MDM2, RB1
69.6CDK4, PTEN, RB1
79.5CDK4, IGF1R, RB1
89.4KIT, MET, PTEN
99.4CDK4, CDKN2A, MDM2, RB1
109.4CDK4, CDKN2A, MDM2, RB1
11
Show member pathways
9.4CDK4, CDKN2A, MDM2, RB1
129.4CDK4, CDKN2A, MDM2, RB1
139.4CDK4, MDM2, PTEN, RB1
14
Show member pathways
9.4CDK4, MDM2, PTEN, RB1
15
Show member pathways
9.4CDK4, MDM2, PTEN, RB1
169.3MDM2, MET, PTEN, RB1
179.3CDKN2A, HMGA2, MDM2, MET, PTEN
189.2IGF1R, KIT, MDM2, MET
19
Show member pathways
9.2IGF1R, MDM2, MET, PTEN, STAT6
209.2CALR, CDK4, CDKN2A, RB1
219.2CALR, MDM2, PTEN, RB1
22
Show member pathways
9.1CDK4, CDKN2A, MDM2, PTEN, RB1
239.0CDKN2A, IGF1R, MDM2, PTEN, RB1
249.0CEBPA, PPARG, RB1, STAT6
25
Show member pathways
8.9CALR, CDK4, PTEN, RB1, STAT6
26
Show member pathways
8.9CEBPA, IGF1R, KIT, MDM2, PTEN
27
Show member pathways
8.8CDK4, CDKN2A, MDM2, PSMD10, RB1
288.8CDK4, CDKN2A, IGF1R, MDM2, PTEN, RB1
298.8CEBPA, MDM2, MET, PPARG, RB1
30
Show member pathways
8.8CDK4, IGF1R, MDM2, MET, PTEN, RB1
318.8CEBPA, HMGA2, IGF1R, MDM2, MET, PPARG
328.7CDK4, IGF1R, KIT, MDM2, MET, PTEN
33
Show member pathways
8.5CDK4, CDKN2A, IGF1R, MDM2, MET, PTEN
34
Show member pathways
8.3CEBPA, IGF1R, KIT, MDM2, MET, PTEN
358.2FRS2, IGF1R, MDM2, MET, SDC1
368.2CEBPA, DES, KIT, PPARG, SDC1
37
Show member pathways
7.6CDK4, CEBPA, FRS2, KIT, MET, PPARG
38
Show member pathways
7.5CDK4, CDKN2A, DES, IGF1R, KIT, MDM2
397.3CDK4, CDKN2A, CEBPA, IGF1R, KIT, MDM2

GO Terms for genes affiliated with Dedifferentiated Liposarcoma

About this section

Biological processes related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

(show all 22)
idNameGO IDScoreTop Affiliating Genes
1senescence-associated heterochromatin focus assemblyGO:003598610.7CDKN2A, HMGA2
2negative regulation of intracellular steroid hormone receptor signaling pathwayGO:003314410.5CALR, HMGA2
3negative regulation of cyclin-dependent protein serine/threonine kinase activityGO:004573610.4CDKN2A, CEBPA
4white fat cell differentiationGO:005087210.4CEBPA, PPARG
5cellular response to lithium ionGO:007128510.3CALR, CEBPA
6protein localization to nucleusGO:003450410.3CALR, MDM2
7somatic stem cell divisionGO:004810310.3CDKN2A, KIT
8protein stabilizationGO:005082110.0CALR, CDKN2A, PTEN
9negative regulation of G1/S transition of mitotic cell cycleGO:200013410.0PTEN, RB1
10cell cycle arrestGO:000705010.0CALR, CDKN2A, RB1
11positive regulation of cell proliferationGO:00082849.8CDK4, HMGA2, MDM2, PTEN
12positive regulation of transcription, DNA-templatedGO:00458939.3CDKN2A, CEBPA, HMGA2, PPARG, RB1
13regulation of cell cycleGO:00517269.3CDK4, PTEN, RB1
14negative regulation of apoptotic processGO:00430669.2ACTC1, HMGA2, MDM2, PSMD10, PTEN
15phosphatidylinositol-mediated signalingGO:00480159.2FRS2, IGF1R, KIT, MDM2, PTEN
16response to toxic substanceGO:00096369.1CDK4, MDM2, SDC1
17regulation of transcription, DNA-templatedGO:00063559.1CALR, CEBPA, HMGA2, PPARG, STAT6
18negative regulation of transcription, DNA-templatedGO:00458929.0CALR, CEBPA, HMGA2, PPARG, RB1
19Fc-epsilon receptor signaling pathwayGO:00380958.9FRS2, MDM2, PSMD10, PTEN
20fibroblast growth factor receptor signaling pathwayGO:00085438.8FRS2, KIT, MDM2, PSMD10, PTEN
21signal transductionGO:00071658.6CDK4, HMGA2, IGF1R, KIT, MET, PPARG
22positive regulation of transcription from RNA polymerase II promoterGO:00459448.4CDKN2A, CEBPA, HMGA2, MET, PPARG, RB1

Sources for Dedifferentiated Liposarcoma

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet